中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物制剂研究中心
Cytokines enhance nitric oxide production from human BT325 astrocytoma cells

文献类型：期刊论文

作者Zhao, HW; Li, XY
刊名ACTA PHARMACOLOGICA SINICA
出版日期1999-08
卷号20期号:8页码:759-762
关键词astrocytoma cultured tumor cells interleukin-1 interleukin-2 tumor necrosis factor interferon type II lipopolysaccharides nitric oxide
ISSN号0253-9756
文献子类Article
英文摘要AIM: To study the effects of lipopolysaccharides (LPS) and pre-inflammatory cytokines on nitric oxide ( NO) production from cultured astrocytes. METHODS: Nitrites in supernatants were measured with Griess assay. RESULTS: The NO production from cultured human BT325 astrocytoma cells started when cultured for 4 h, reached the peak concentration (15.0 mu mol.L-1) at 12 h, maintained a high level (15.0-17.5 mu mol.L-1) up to 72 h, and was enhanced by LPS 1 mg.L-1, interferon-gamma (IFN-gamma) 100 kU . L-1, tumor necrosis factor-alpha (TNF-alpha) 100 kU . L-1 interleukin (IL)-1 100 kU . L-1, or IL-2 100 kU . L-1 The enhancements of TNF-alpha, IL-1, IL-2, or the mixture of the above four cytokines were higher. CONCLUSION: Stimulants and pre-inflammatory cytokines enhance astrocytes producing NO.
WOS关键词BETA
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000081902700019
出版者ACTA PHARMACOLOGICA SINICA
源URL[http://119.78.100.183/handle/2S10ELR8/274710]  
专题药物制剂研究中心
通讯作者Li, XY
作者单位Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China
推荐引用方式
GB/T 7714		 Zhao, HW,Li, XY. Cytokines enhance nitric oxide production from human BT325 astrocytoma cells[J]. ACTA PHARMACOLOGICA SINICA,1999,20(8):759-762.
APA Zhao, HW,&Li, XY.(1999).Cytokines enhance nitric oxide production from human BT325 astrocytoma cells.ACTA PHARMACOLOGICA SINICA,20(8),759-762.
MLA Zhao, HW,et al."Cytokines enhance nitric oxide production from human BT325 astrocytoma cells".ACTA PHARMACOLOGICA SINICA 20.8(1999):759-762.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。